IBR says new botanical combination is effective, non-steroidal alternative for skin relief

03-Jan-2012 - Last updated on 13-Mar-2017 at 19:37 GMT

Related tags Effectiveness Clinical trial

Working from the knowledge that over 40 per cent of the population tends to suffer from skin discomfort and sensitivity, cosmetics ingredients supplier IBR has developed a natural alternative to steroid-based treatments that has been shown in clinical trials to be as effective as Hydrocortisone one per cent cream in providing skin relief.

According to IBR, while skin complaints such as sensitivity and discomfort are common, only limited options are available to sufferers. Such options often contain steroids, which have limitations in terms of the period of use and can produce side effects.

As a result, the company developed IBR-ProPhyDerm as a natural, alternative solution. In addition to tackling skin sensitivity and discomfort, the botanical complex is said to be ideal for everyday maintenance skin care.

Synergistic effect on reducing skin irritation and sensitivity

IBR-ProPhyDerm is a patent-protected combination of two of IBR’s botanical actives: Narcissustazetta bulbs extract (IBR-Dormin) and a naturally sourced extract of phytoene and phytofluene carotenoids (IBR-TCLC/IBR-CLC).

In in vitro tests, using a modified version of the HET CAM model, the complex was discovered to have a synergistic effect on reducing skin irritation and sensitivity. A carrier o/w cream was formulated and the effect of each active alone on reducing irritation in pre-irritated tissue was compared to that of the actives in combination.

Results indicated that the IBR-ProPhyDerm complex (2 per cent IBR-Dormin all natural 0305 and 2 per cent IBR-TCLC in Squalane 0702 in carrier) displayed a more pronounced protective effect against induced irritation in comparison to the actives in isolation.

Clinical trial

Additionally, a 28-day clinical trial comparing the effect of the IBR-ProPhyDerm cream to Hydrocortisone one per cent cream was carried out among 26 people suffering from mild to moderate chronic eczema, with clinical assessment points taking place every seven days.

According to IBR, both treatments where shown to have resulted in a 70 per cent improvement in the appearance and sensation of skin manifestations such as erythema, redness, itching and scaling, after four weeks of use.

For both treatments, the total scoring and efficacy index was identical at the end of the clinical trial, IBR notes, demonstrating that the steroid-free IBR-ProPhyDerm formula delivers an equivalent level of skin relief to that of Hydrocotisone one per cent.